Simponi Aria (also known by its generic name golimumab) is a a TNF-alpha inhibitor that was approved by the FDA in October 2017 to treat adults with active psoriatic arthritis. In September 2020, the indication was extended to include pediatric patients 2 years and older. Simponi Aria is also approved to treat rheumatoid arthritis, ankylosing spondylitis, and polyarticular juvenile idiopathic arthritis.
For adults with active psoriatic arthritis, the Simponi Aria is given in a doctor's office as an intravenous infusion over 30 minutes at weeks 0 and 4, and every 8 weeks thereafter. For pediatric patients with psoriatic arthritis, the Simponi Aria is given in a doctor's office as an intravenous infusion over 30 minutes at weeks 0 and 4, and every 8 weeks thereafter.
To learn more, please visit the Simponi Aria website.
